Advertisement

Bluebird bio, a Cambridge genetics-focused biotech firm, has entered into a deal, worth up to $4.2 million, with the French Muscular Dystrophy Association (AFM). The agreement focuses on the development of LentiGlobin, a treatment intended for beta-thalassemia and sickle cell anemia.

The company will take in about $1.4 million in an upfront cash payment to support LentiGlobin’s development. Another $2.8 million in credit may be used by bluebird bio to manufacture cGMP clinical trial material at AFM-developed nonprofit research center Généthon, where bluebird has an existing gene therapy manufacturing agreement.

SOURCE

Advertisement
Advertisement